The under 65 year olds with unmet treatment are 70% of the...

The under 65 year olds with unmet treatment are 70% of the patient pool for HR+/HER2– MBC (79% in AIPAC IIb) and add to it low monocytes and luminal Bs.

So, the overall survival for overall population was not a fair representation of the success of the trial, beside the fact that now they know they should not have discontinued Taxol after 24 weeks. So, watch this space ... Not just with the AIPAC-003 coming but the attention that the results have in all likelihood attracted, ... those who matter that is- big pharma - and will more than likely for example reflect in partnership for AIPAC-003, of course as well as serious investors who are building up, which hopefully make the floating short term pond smaller and smaller.

The latter in evident from the fact that the total volume of those who sold through this last week has been way less than what we used to see previously. Total sell off volume over the temporary course of a decline are decreasing each time - also meaning strong hold by serious investors - and that is how you see the safety net, baseline, in the chart steadily climbing with progress. These are the ones who will really matter IF it comes to take over - not a few short term traders with a handful of shares.